Efficacy of danazol in a patient with congenital Protein S deficiency: Paradoxical evidence for decreased platelet activation with increased thrombin generation

Thrombosis Research

Volumn 87, Issue 5, 1997, Pages 473-482

  Ledford, Marlies R ^a   Horton, Allan ^b   Wang, Grace ^c   Brito, Maria ^a   Delgado, Luz ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BECKMAN COULTER INC   (United States)

^c BAPTIST HOSPITAL OF MIAMI   (United States)

Author keywords

CD62(P Selectin); Danazol; Protein S deficiency; Prothrombin fragment 1.2 (F1.2); Thrombin antithrombin (TAT)

Indexed keywords

DANAZOL; WARFARIN;

ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; ANTICOAGULANTS; CELL SEPARATION; DANAZOL; ESTROGEN ANTAGONISTS; FIBRINOLYSIS; FLOW CYTOMETRY; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PROTEIN S DEFICIENCY; THROMBIN; WARFARIN;

EID: 0030750504     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00163-1     Document Type: Article

References (37)

1. DAHLBÄCK, B. The Protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 77, 1-43, 1995.
2. MICHIELS, J.J., STIBBE, J., BERTINA, R., BROEKMANS, A. Effectiveness of long term oral anticoagulation treatment in preventing venous thrombosis in hereditary Protein S deficiency. Br Med J 295, 641-643, 1987.
3. PESCATOR, E.P., HORELLOU, H.M., CONARD, J., PIFFOUX, M., VAN DREDEN, P., RUSKONE-FOURMESTRAUX, A., SAMAMA, M. Problems of oral anticoagulation in an adult with homozygous Protein C deficiency and late onset of thrombosis. Thromb Haemostas 69, 311-315, 1993.
4. GRIMAUDO, V., GUEISSAZ, F., HAUERT, J., SARRA, J.A., KRUITHOF, E.K.O., BACHMANN, F. Necrosis of skin induced by coumarin in a patient deficient in Protein S. Br Med J 298, 233-234, 1989.
5. THORISDOTTIR, H., EVANS, J.A., SCHWARTZ, H.J., COMP, P., HALUSCHAK, J. RATNOFF, O.D. Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. J Lab Clin Med 119, 698-701, 1992.
6. SHIMMYOZU, K., KADOKURA, N., TARA, M., MARUYAMA, I., OSAME, M. Effects of danazol on plasma levels of Protein S and C4b-binding protein. Japan J Clin Hematol 31, 860-861, 1990.
7. LAURELL, C.B., RANNEVIK, G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endrocrinol Metab 49, 719-725, 1979.
8. AGOSTONI, A., CICARDI, M., MARTIGNONI, G.C., BERGAMASCHINI, L., MARASINI, B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 65, 75-79, 1980.
9. SHEFFER, A.L., FEARON, D.T., AUSTEN, K.F. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 68, 181-187, 1981.
10. FIESSINGER, J.N., AIACH, M. Stanozolol treatment in an AT III deficient patient (letter). Thromb Haemostas 43, 183, 1980.
11. WINTER, J.H., FENECH, A., BENNETT, B., DOUGLAS, A.S. Prophylactic antithrombotic therapy with stanozolol in patients with familial Antithrombin III deficiency. Br J Haematol 57, 527-537, 1984.
12. FAIRFAX, A.J., IBBOTSON, R.M. Danazol raises Antithrombin III levels in cases of familial deficiency. Lancet ii, 1272-1273, 1984.
13. EYSTER, M.E., PARKER, M.E. Treatment of familial Antithrombin-III deficiency with danazol. Haemostas 15, 119-125, 1985.
14. MILLER, N., HUTLIN, M.B., GOUNDER, M., ZARRABI, M.H. Hereditary Antithrombin III deficiency: case report and review of recent therapeutic advances. Am J Hematol 21, 215-221, 1986.
15. SHIBUYA, A., NINOMIYA, H., NAKAZAWA, M., NAGASAWA, T., YODA, Y., ABE, T. Oxymetholone therapy in patients with familial Antithrombin III deficiency. Thromb Haemostas 60, 495-497, 1988.
16. KLUFT, C., BERTINA, R.M., PRESTON, F.E., MALIA, R.G., BLAMEY, S.L., LOWE, G.D.O., FORBES, C.D. Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. Thromb Res 33, 297-304, 1984.
17. GONZALEZ, R., ALBERCA, I., SALA, N., VICENTE, V. Protein C deficiency-response to danazol and DDAVP. Thromb Haemostas 53, 320-322, 1985.
18. BROEKMANS, A.W., CONRAD, J., van WEYENBERG, R.G., HORELLOU M.H., KLUFT, C., BERTINA R.M. Treatment of hereditary Protein C deficiency with stanozolol. Thromb Haemostas 57, 20-24, 1987.
19. GRUPPO, R.A., LEIMER, P., FRANCIS, R.B., MARLAR, R.A., SILBERSTEIN, E. Protein C deficiency resulting from possible double heterozygosity and its response to danazol. Blood 71, 370-374, 1988.
20. AL-MOMEN A.K., GADER, A.M.A., SHAMENA, A.R., DAIF, A.K., AJARIM, D. Significant elevation of Protein C and Protein S levels in thrombotic disorders by low dose danazol. Blood Coag Fibrinol 2, 495-499, 1991.
21. RUIZ-ARGUELLES, G.J., RUIZ-ARGUELLES, A., PEREZ-ROMANO, B., ALARCON-SEGOVIA, D. Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol. Acta Haematol 89, 206-208, 1993.
22. KESTIN, A.S., VALERI, C.R., KHURI, S.F., LOSCALZO, J., ELLIS, P.A., MACGREGOR, H., BIRJINIUK, V., OUIMET, H., PASCHE, B., NELSON, M.J., BENOIT, S.E., RODINO, L.J., BARNARD, M.R., MICHELSON, A.D. The platelet function defect of cardiopulmonary bypass. Blood 82, 107-117, 1993.
23. KIRSCHBAUM, N.E., FOSTER, P.A. The polymerase chain reaction with sequence specific primers for the detection of the Factor V mutation associated with activated Protein C resistance. Thromb Haemostas 74, 874-878, 1995.
24. BELLISSIMO, D.B., KIRSCHBAUM, N.E., FOSTER, P.A. Improved method for Factor V Leiden typing by PCR-SSP (letter). Thromb Haemostas 75, 520, 1996.
25. HENKE, W.J. Protein C and S response to danacrine in end-stage renal disease (letter). Ann Intern Med 106, 910, 1988.
26. BOWER, W. A., HUMPHRIES, J.E. Failure of the synthetic androgen, danazol, to increase Protein S levels and prevent thrombosis in a patient with severe Protein S deficiency. Haemostas 25, 144-148, 1995.
27. HUMPHRIES, J.E. Acquired Antithrombin III deficiency: replacement with Antithrombin IIII concentrates in a patient with Protein S deficiency accelerates response to therapy. Acta Haematol 90, 151-154, 1993.
28. KOELEMAN, B.P.C., REITSMA, P.H., ALLAART, C.F., BERTINA, R.M. Activated Protein C Resistance as an additional risk factor for thrombosis in Protein C-deficient families. Blood 84, 1031-1035, 1994.
29. SAIDI, P., LEGA, B.Z., KIM, H.C., RASKA, K. Effect of danazol on clotting factor levels, bleeding incidence, factor infusion requirements, and immune parameters in hemophilia. Blood 68, 673-679, 1986.
30. SHIGEKIYO, T., TOMONARI, A., UNO, Y., KISHI, Y. Danazol therapy in hypoplasminogenemia (letter). Thromb Haemostas 68, 233-234, 1992.
31. KLUFT, C., PRESTON, F.E., MALIA, R.G., BERTINA, R.M., WIJNGAARDS, G., GREAVES, M., VERHEIJEN, J.H., DOOIJEWAARD, G. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 51, 157-164, 1984.
32. MANNUCCI, P.M., KLUFT, C., TRAAS, D.W., SEVESO, P., D'ANGELO, A. Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. Br J Haematol 63, 753-759, 1986.
33. 1+2 fragment and thrombinantithrombin complex. Blood 59, 1086-1097, 1982.
34. BONFANTI, R., FURIE, B.C., FURIE, B., WAGNER, D.D. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 73, 1109-1112, 1989.
35. COLLINS, P.W., MACEY, M.G., CAHILL, M.R., NEWLAND, A.C. Von Willebrand Factor release and P-selectin expression is stimulated by thrombin and trypsin but not by IL-1 in cultured human endothelial cells. Thromb Haemostas 70, 346-350, 1993.
36. PALABRICA, T, LOBB, R., FURIE, B.C., ARONOVITZ, M., BENJAMIN, C., HSU, Y., SAJER, S.A., FURIE, B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets (letter). Nature 359, 848-851, 1992.
37. FURIE, B., FURIE, B.C. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemostas 74, 224-227, 1995.